Skip to main content
Figure 2 | BMC Gastroenterology

Figure 2

From: Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma

Figure 2

Anti-tumour effects: levels of tumour markers. Time-dependent levels of α-fetoprotein (a–c) and des-γ-carboxy prothrombin (d–f) after combination therapy of IA-call® and miriplatin at levels 1 (a, d), 2 (b, e) and 3 (c, f). Tumour markers are represented as white circles in cases 1, 4 and 7; grey circles in cases 2, 5 and 8 and black circles in cases 3, 6 and 9. PR, partial response; SD, stable disease; PD, progressive disease; N/A, not applicable for the response evaluation

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us